EU AI Act Amendments Get Green Light From Parliament Committees In Latest Vote

 
• By Eliza Slawther
  
Generate a summary of this article
Listen to this article
Beta

The European Commission’s hotly debated AI Act proposal is a step closer to becoming law after 13 amendments were voted in by members of the European Parliament. The landmark legislation is set to have an enormous impact on all AI products, including many medical devices.

EU Vote
• Source: Shutterstock

A wave of claps erupted in the European Parliament this morning after members voted by a “large majority” in favor of 13 amendments to the Artificial Intelligence (AI) Act, meaning the controversial regulatory proposal is one step closer to becoming law. This development is one that is set to have large implications for the medtech sector, as once the AI Act is adopted it will set new compliance requirements for many medical devices (more below.)

In total, 84 members of the Internal Market and Consumer Protection (IMCO) and the Civil Liberties, Justice and Home Affairs...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Europe

Global Medtech Guidance Tracker: September 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

 
• By Natasha Barrow

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.

J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US

Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.

Pilot To Program: FDA Issues Accreditation Scheme For Conformity Assessment Draft Guidances

 
• By Brian Bossetta

The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.

More from Geography

Pilot To Program: FDA Issues Accreditation Scheme For Conformity Assessment Draft Guidances

 
• By Brian Bossetta

The US FDA has published a trio of draft guidance documents for its Assessment Scheme for Conformity Program, which began as a pilot in September 2020 to capitalize on the role of standards in the regulation of medical devices.

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

 
• By Natasha Barrow

US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.